Thomas Harth
Ysios Capital
Thomas is a Partner at Ysios Capital, where he is responsible for identifying and evaluating investment opportunities. Prior to joining Ysios, Thomas was Senior Associate at Gimv within the Health & Care team working out of the Antwerp office. He was focused on early-stage Life Sciences investments. Thomas co-led the investments in Anjarium Biosciences and Kinaset Therapeutics and was involved with portfolio companies Fire1, ONWARD (Euronext – ONWD), Biotalys (Euronext – BTLS), JenaValve, and Breath Therapeutics (sold to Zambon).
In addition to Tagworks, he serves on the boards of Memo Therapeutics and Anaconda Biomed.
Thomas holds a master’s degree in bioengineering and applied economics, both from the University of Ghent.
Curious about what we do? Get in touch!
Contact
T +31 85 800 8550
info@tagworkspharma.com
Address
Tagworks Pharmaceuticals BV
Toernooiveld 1
6525 ED Nijmegen
The Netherlands
Stay updated
© Tagworks Pharmaceuticals, 2024 | Terms of use | Design by Ape to Zebra